BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 8725700)

  • 1. Pharmacokinetics of depot medroxyprogesterone acetate contraception.
    Mishell DR
    J Reprod Med; 1996 May; 41(5 Suppl):381-90. PubMed ID: 8725700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians.
    Kaunitz AM
    Int J Fertil Womens Med; 1998; 43(2):73-83. PubMed ID: 9609206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA.
    Ortiz A; Hirol M; Stanczyk FZ; Goebelsmann U; Mishell DR
    J Clin Endocrinol Metab; 1977 Jan; 44(1):32-8. PubMed ID: 833262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): assessment of return of ovulation after three monthly injections in surgically sterile women.
    Rahimy MH; Ryan KK
    Contraception; 1999 Oct; 60(4):189-200. PubMed ID: 10640165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statement on injectable contraception.
    International Planned Parenthood Federation IPPF
    IPPF Med Bull; 1982 Dec; 16(6):3-4. PubMed ID: 12338511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endometrial histology and circulating levels of medroxyprogesterone acetate (MPA), estradiol, FSH and LH in women with MPA induced amenorrhoea compared with women with secondary amenorrhoea.
    Jeppsson S; Johansson ED; Ljungberg O; Sjöberg NO
    Acta Obstet Gynecol Scand; 1977; 56(1):43-8. PubMed ID: 842303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): steady-state pharmacokinetics of MPA and E2 in surgically sterile women.
    Rahimy MH; Ryan KK; Hopkins NK
    Contraception; 1999 Oct; 60(4):209-14. PubMed ID: 10640167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New aspects of injectable contraception.
    Phillips OP
    Int J Fertil Womens Med; 2001; 46(1):31-6. PubMed ID: 11294618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depo provera in perspective.
    McGoldrick IA
    P N G Med J; 1981 Dec; 24(4):274-9. PubMed ID: 6461984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously.
    Segall-Gutierrez P; Taylor D; Liu X; Stanzcyk F; Azen S; Mishell DR
    Contraception; 2010 Jun; 81(6):487-95. PubMed ID: 20472115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104 mg/0.65 mL) contraceptive formulation in Asian women.
    Toh YC; Jain J; Rahnny MH; Bode FR; Ross D
    Clin Ther; 2004 Nov; 26(11):1845-54. PubMed ID: 15639696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medroxyprogesterone acetate and estradiol cypionate injectable suspension (Cyclofem) monthly contraceptive injection: steady-state pharmacokinetics.
    Thurman A; Kimble T; Hall P; Schwartz JL; Archer DF
    Contraception; 2013 Jun; 87(6):738-43. PubMed ID: 23265980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of depo-provera in teens.
    Khoiny FE
    J Pediatr Health Care; 1996; 10(5):195-201. PubMed ID: 8920351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Counseling issues and management of side effects for women using depot medroxyprogesterone acetate contraception.
    Nelson AL
    J Reprod Med; 1996 May; 41(5 Suppl):391-400. PubMed ID: 8725701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of long-term treatment with depot medroxy progesterone acetate for contraception on estrogenic activity.
    Taneepanichskul S; Patrachai S
    J Med Assoc Thai; 1998 Dec; 81(12):944-6. PubMed ID: 9916381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of levonorgestrel implants with depo-medroxyprogesterone acetate injections for contraception.
    London RS
    J SOGC; 1993 Oct; 15(8):925-8, 32. PubMed ID: 12318530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depo-Provera use in an Australian metropolitan practice.
    Fraser IS; Dennerstein GJ
    Med J Aust; 1994 May; 160(9):553-6. PubMed ID: 8164553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.
    Kaunitz AM; Darney PD; Ross D; Wolter KD; Speroff L
    Contraception; 2009 Jul; 80(1):7-17. PubMed ID: 19501210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): effects of body weight and injection sites on pharmacokinetics.
    Rahimy MH; Cromie MA; Hopkins NK; Tong DM
    Contraception; 1999 Oct; 60(4):201-8. PubMed ID: 10640166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.